Atypical mycobacteria: Showerheads, anti-TNF therapy and Crohn's disease

Expert Review of Clinical Immunology

Volumn 6, Issue 5, 2010, Pages 695-699

  Desai, Alka A ^a   Marks, Daniel J B ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

adalimumab; anti TNF; Crohns disease; etanercept; infliximab; mycobacteria; rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ETANERCEPT; INFLIXIMAB; TUMOR NECROSIS FACTOR ANTIBODY;

ATYPICAL MYCOBACTERIUM; CROHN DISEASE; EDITORIAL; HUMAN; INFECTION RISK; MYCOBACTERIOSIS; MYCOBACTERIUM AVIUM; PREVALENCE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; IMMUNOSUPPRESSION; IMMUNOTHERAPY; MYCOBACTERIA, ATYPICAL; MYCOBACTERIUM INFECTIONS, ATYPICAL; RECURRENCE; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77956542379     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/eci.10.61     Document Type: Editorial

References (51)

1. Dalziel TK. Chronic intestinal enteritis. Br. Med. J. 2, 1068-1070 (1913).
2. Chacon O, Bermudez LE, Barletta RG. Johne's disease, infammatory bowel disease, and Mycobacterium paratuberculosis. Annu. Rev. Microbiol. 58, 329-363 (2004).
3. Chiodini RJ, Van Kruiningen HJ, Thayer WR, Coutu JA. Spheroplastic phase of mycobacteria isolated from patients with Crohn's disease. J. Clin. Microbiol. 24(3), 357-363 (1986).
4. Feller M, Huwiler K, Stephan R et al. Mycobacterium avium subspecies paratuberculosis and Crohn's disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7(9), 607-613 (2007).
5. Marks DJ, Mitchison NA, Segal AW, Sieper J. Can unresolved infection precipitate autoimmune disease? Curr. Top. Microbiol. Immunol. 305, 105-125 (2006).
6. Peyrin-Biroulet L, Neut C, Colombel JF. Antimycobacterial therapy in Crohn's disease: game over? Gastroenterology 132(7), 2594-2598 (2007).
7. Selby W, Pavli P, Crotty B et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn's disease. Gastroenterology 132(7), 2313-2319 (2007).
8. Gitlin L, Biesecker J. Australian Crohn's antibiotic study opens new horizons. Gastroenterology 133(5), 1743-1744 (2007).
9. Flynn JL, Goldstein MM, Chan J et al Tumor necrosis factor-a is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 2(6), 561-572 (1995).
10. Beutler B, Cerami A. The biology of cachectin/TNF-a primary mediator of the host response. Annu. Rev. Immunol. 7, 625-655 (1989).
11. Roach DR, Bean AG, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J. Immunol. 168(9), 4620-4627 (2002).
12. Lugering A, Schmidt M, Lugering N, Pauels HG, Domschke W, Kucharzik T Infiximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 121(5), 1145-1157 (2001).
13. Van den Brande JM, Braat H, van der Brink GR et al. Infiximab but not etanercept induces apoptosis in lamina propria T lymphocytes from patients with Crohn's disease. Gastroenterology 124(7), 1774-1785 (2003).
14. Ehrenstein MR, Evans JG, Singh A et al Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFa therapy. J. Exp. Med. 200(3), 277-285 (2004).
15. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect. Dis. 3(9), 578-590 (2003).
16. Ray JC, Flynn JL, Kirschner DE. Synergy between individual TNF-dependent functions determines granuloma performance for controlling Mycobacterium tuberculosis infection. J. Immunol. 182(6), 3706-3717 (2009).
17. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin. Infect. Dis. 38(9), 1261-1265 (2004).
18. Keane J, Gershon S, Wise RP et al Tuberculosis associated with infiximab, a tumor necrosis factor a-neutralizing agent. N. Engl. J Med. 345(15), 1098-1104 (2001).
19. Behr MA. Mycobacterium du jour: what's on tomorrow's menu? Microbes Infect. 10(9), 968-972 (2008).
20. Feazel LM, Baumgartner LK, Peterson KL, Frank DN, Harris JK, Pace NR. Opportunistic pathogens enriched in showerhead bioflms. Proc. Natl Acad. Sci. USA 106(38), 16393-16399 (2009).
21. Lambrecht RS, Carriere JF, Collins MT A model for analyzing growth kinetics of a slowly growing Mycobacterium sp. Appl Environ. Microbiol. 54(4), 910-916 (1988).
22. Richter E, Wessling J, Lugering N, Domschke W, Rüsch-Gerdes S. Mycobacterium avium subsp. paratuberculosis infection in a patient with HIV, Germany. Emerg Infect. Dis. 8(7), 729-731 (2002).
23. Winthrop KL, Chang E, Yamashita S, Iademarco MF, LoBue PA. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-a therapy. Emerg Infect. Dis. 15(10), 1556-1561 (2009).
24. Cassidy PM, Hedberg K, Saulson A, McNelly E, Winthrop KL. Nontuberculous mycobacterial disease prevalence and risk factors: a changing epidemiology. Clin. Infect. Dis. 49(12), e124-e129 (2009).
25. Olsen I, Tollefsen S, Aagaard C et al Isolation of Mycobacterium avium subspecies paratuberculosis reactive CD4 T cells from intestinal biopsies of Crohn's disease patients. PLoS ONE 4(5), e5641 (2009).
26. Stabel JR. Temporal effects of tumor necrosis factor-a on intracellular survival of Mycobacterium paratuberculosis. Vet. Immunol. Immunopathol. 45(3-4), 321-332 (1995).
27. Hugot JP, Chamaillard M, Zouali H et al Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature 411(6837), 599-603 (2001).
28. Marks DJ, Harbord MW, MacAllister R et al. Defective acute infammation in Crohn's disease: a clinical investigation. Lancet 367(9511), 668-678 (2006).
29. Smith AM, Rahman FZ, Hayee B et al. Disordered macrophage cytokine secretion underlies impaired acute infammation and bacterial clearance in Crohn's disease. J. Exp. Med. 206(9), 1883-1897 (2009).
30. Sewell GW, Marks DJ, Segal AW. The immunopathogenesis of Crohn's disease: a three-stage model. Curr. Opin. Immunol. 21(5), 506-513 (2009).
31. Marks DJ, Rahman FZ, Sewell GW, Segal AW. Crohn's disease: an immune defciency state. Clin. Rev. Allergy Immunol 38(1), 20-31 (2010).
32. Harris J, Keane J. How tumour necrosis factor blockers interfere with tuberculosis immunity. Clin. Exp. Immunol. 161(1), 1-9 (2010).
33. Mufti AH, Toye BW, McKendry RR, Angel JB. Mycobacterium abscessus infection after use of tumor necrosis factor a inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor a inhibitor use. Diagn. Microbiol. Infect. Dis. 53(3), 233-238 (2005).
34. Martin-Aspas A, Guerrero-Sánchez F, Garcia-Martos P, González-Moya E, Medina-Varo F, Girón González JA. Bilateral pneumonia by Mycobacterium aurum in a patient receiving infiximab therapy. J. Infect. 57(2), 167-169 (2008).
35. Okubo H, Iwamoto M, Yoshio T et al. Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infiximab. Mod. Rheumatol. 15(1), 62-64 (2005).
36. Salvana EM, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infiximab-treated patients. J. Infect. 55(6), 484-487 (2007).
37. Larsen MV, Sørensen IJ, Thomsen VO, Ravn P. Re-activation of bovine tuberculosis in a patient treated with infiximab. Eur. Resp. J. 32(1), 229-231 (2008).
38. Boulman N, Rozenbaum M, Slobodin G, Rosner I. Mycobacterium fortuitum infection complicating infiximab therapy in rheumatoid arthritis. Clin. Exp. Rheumatol. 24(6), 723 (2006).
39. Vilela Lopes R, Barros Ohashi C, Helena Cavaleiro L et al. Development of leprosy in a patient with ankylosing spondylitis during the infiximab treatment: reactivation of a latent infection? Clin. Rheumatol. 28(5), 615-617 (2009).
40. Fallon JC, Patchett S, Gulmann C, Murphy GM. Mycobacterium marinum infection complicating Crohn's disease, treated with infiximab. Clin. Exp. Dermatol. 33(1), 43-45 (2008).
41. Ramos JM, Garcia-Sepulcre MF, Rodriguez JC, Padilla S, Gutiérrez F. Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy. J. Med. Microbiol. 59(5), 617-621 (2010).
42. Marie I, Heliot P, Roussel F, Herve? F, Muir JF, Levesque H. Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infiximab. Rheumatology 44(9), 1201-1202 (2005).
43. Chopra N, Kirschenbaum AE, Widman D. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J. Clin. Rheumatol. 8(5), 265-268 (2002).
44. Elyousf AA, Leiter JR, Goytan MJ, Robinson DB. Mycobacterium heckeshornense lumbar spondylodiskitis in a patient with rheumatoid arthritis receiving etanercept treatment. J. Rheumatol. 36(9), 2130-2131 (2009).
45. Shehan JM, Sarma DP. Mycobacterium mucogenicum: report of a skin infection associated with etanercept. Dermatol. Online J. 14(1), 5 (2008).
46. Maimon N, Brunton J, Chan AK, Marras TK. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. Thorax 62(8), 739-740 (2007).
47. Yim K, Nazeer SH, Kiska D, Rose FB, Brown D, Cynamon MH. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. Scand. J. Infect. Dis. 36(2), 150-154 (2004).
48. Diaz F, Urkijo JC, Mendoza F et al. Mycobacterium chelonae infection associated with adalimumab therapy. Scand. J. Rheumatol. 37(2), 159-160 (2008).
49. Kluger N, Cohen P, Fallet-Bianco C, Guillevin L. Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis. Clin. Exp. Rheumatol. 28(1), 101-102 (2010).
50. Swart RM, van Ingen J, van Soolingen D, Slingerland R, Hendriks WD, den Hollander JG. Nontuberculous mycobacteria infection and tumor necrosis factor-a antagonists. Emerg. Infect. Dis. 15(10), 1700-1701 (2009).
51. Van Ingen J, Boeree M, Janssen M et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. Nat. Clin. Pract. Rheumatol. 3(7), 414-419 (2007).